Sorrento Therapeutics, Inc. · OTC:SRNE

Sorrento Therapeutics — Investor Presentation (January 2021)

36 slides from Sorrento Therapeutics's investor presentation, Jan 11, 2021

  1. Slide 1: Saving Life Medicine

    Saving Life TM Medicine January 20 21 NASDAQ : SRNE © 2021 Sorrento Therapeutics, Inc. All Rights Reserved 1 Exhibit 99.1

  2. Slide 2: Forward-looking statements

    Certain statements contained in this presentation or in other documents of Sorrento Therapeutics, Inc . (the “Company” or “Sorrento”) and of any of its affiliates, along with certain statements that may be made by management of the Company orally in presenting this material, are or may be considered

  3. Slide 3: About the Company

    About the COMPANY • Funded and Operational in 2009 • NASDAQ: SRNE • HQ in San Diego, CA ~ 500 Employees worldwide ~100 Employees with PhDs & MDs ~ 300,000 SF Research and cGMP Manufacturing Facilities • 5 cGMP Manufacturing Sites (4 USA, 1 China) mAbs, Small Molecule, ADC, Plasmid DNA, Cell Therapie

  4. Slide 4: Sorrento Corporate Infrastructure

    Sorrento Corporate Infrastructure Legal & Finance cGMP MFG Regulatory & ClinOp R&D ~500 Employees 100+ PhD/MD Scientists S & M Drug Discovery Engine IND - enabling Tox Studies Therapeutic Antibody Oncolytic Virus ADC Fill - n - Finish IND Filing (12 IND in 2020) Clinical Trial NDA Filing Sales & Mar

  5. Slide 5: Sorrento G-MAB Toolbox (proprietary)

    Sorrento G - MAB Toolbox ( proprietary ) 5 © 2021 Sorrento Therapeutics, Inc. All Rights Reserved CAR - T, DAR - T, CAR - NK, DAR - NK

  6. Slide 6: Sorrento Platform to Product

    © 2021 Sorrento Therapeutics, Inc. All Rights Reserved Sorrento Platform Product Small Molecule G - MAB ADC Cell ADNAB ADC CAR - T DAR - T SP - 102 Abivertinib I - O mAbs & BsAbs Sofusa Lymphatic Drug Delivery RTX CBD Cynviloq Dx & nAb MSC M F Gene NK NKT GeneMab OV Seprehvir Biologics Seprehvec iDN

  7. Slide 7: Sorrento Platform to Product

    Sorrento Platform to Product Small Molecule G - MAB ADC Cell ADNAB ADC CAR - T DAR - T SP - 102 Abivertinib I - O mAbs & BsAbs RTX CBD Cynviloq MSC M F Gene NK NKT GeneMab OV Seprehvir Biologics Seprehvec iDNAB CD20 (Rituxan) (IIT - P1) PD - L1 (Pre - IND) VEGF (Avastin) (IIT - P1) VEGFR2 (Pre - IND

  8. Slide 8: Sorrento Therapeutics subsidiaries, M&A milestones and equity holdings

    Sorrento Therapeutics Small Molecule G - MAB ADC Cell ADNAB ADC CAR - T DAR - T SP - 102 Abivertinib I - O mAbs & BsAbs lymphatic drug delivery RTX CBD Cynviloq MSC M F Gene NK NKT GeneMab OV Seprehvir Biologics Seprehvec iDNAB FortuneBio * © 2021 Sorrento Therapeutics, Inc. All Rights Reserved Subs

  9. Slide 9: Immuno-Oncology, Non-Opioid Pain Management, COVID-19

    © 2021 Sorrento Therapeutics, Inc. All Rights Reserved 9 Immuno - Oncology Non - Opioid Pain Management COVID - 19 COVI - AMG SP - 102 DAR - T Abivertinib COVI - DROPS COVI - STIX RTX ZTlido ® PD - L1 mAb CD38 ADC Abivertinib COVI - MSC

  10. Slide 10: COVID Programs

    COVID - 19 Programs 10 © 2021 Sorrento Therapeutics, Inc. All Rights Reserved

  11. Slide 11: Detect Early and Treat Timely

    11 Detect Early and Treat Timely © 2021 Sorrento Therapeutics, Inc. All Rights Reserved Nasal Swab Monitor Infection COVI - AMG STI - 2020 - mAb (IV - Push Outpatient) STI - 2099 - mAb (immediate treatment) Saliva

  12. Slide 12: COVID Programs

    12 COVID - 19 Programs Pre - infection Diagnosis Treatment (ascending disease severity) COVI - GeneMAb ™ COVI - TRACE™ COVI - STIX™ COVI - TRACK™ Platinum COVI - DROPS™ (STI - 2099 ) COVI - AMG™ (STI - 2020) COVI - GUARD™ (STI - 1499) Abivertinib (STI - 5656) COVI - MSC™ (STI - 8282) SARS - CoV - 2

  13. Slide 13: COVID Diagnostics

    COVID - 19 Diagnostics 13 © 2021 Sorrento Therapeutics, Inc. All Rights Reserved

  14. Slide 14: COVI-STIX Sensitive and Simple Virus Antigen Test

    » Simple: Eliminates laborious extraction step and is designed for potential point - of - care (moderately trained technicians) or at - home use » Accurate: Rapid and highly sensitive platinum colloid - based lateral flow immunoassay to detect SAR - CoV - 2 virus antigens (98% sensitivity, 100% spec

  15. Slide 15: COVI-TRACE Rapid Point-of-Care SARS-CoV-2 RNA Test

    COVI - TRACE™ Rapid Point - of - Care SARS - CoV - 2 Virus RNA Test » COVI - TRACE: High Sensitivity and Specificity* » Simple Process: Saliva sample without RNA extraction and no need for complex lab equipment » Colorimetric Reading: red = negative, yellow = positive » In - Field and On - Site Resu

  16. Slide 16: COVI-TRACK Platinum Antibody Test

    COVI - TRACK™ Platinum Antibody Test Indicating Recent Infection » This rapid SARS - CoV - 2 IgG/IgM antibody test kit is intended for use initially in clinical laboratories and point of care to quickly identify individuals with anti - SARS - CoV - 2 antibodies present » Enable confirmation of prote

  17. Slide 17: COVID Therapeutics

    COVID - 19 Therapeutics 17 © 2021 Sorrento Therapeutics, Inc. All Rights Reserved

  18. Slide 18: G-MAB Library for Discovery of Neutralizing Antibodies Against COVID-19

    G - MAB Library for Discovery of Neutralizing Antibodies Against COVID - 19 © 2021 Sorrento Therapeutics, Inc. All Rights Reserved 18

  19. Slide 19: COVI-GeneMAb (STI-8472)

    19 Treatment by Intramuscular Injection of STI - 2020 - mAb - encoding DNA Plasmid COVI - GeneMAb™ (STI - 8472) (STI - 2020 - encoded by DNA Plasmid) » DARPA and JPEO awarded contract with funding of up to $34 million for the project “ Gene Mabs: A Scalable, Economic, Gene - Encoded Protective Antib

  20. Slide 20: COVI-GUARD (STI-1499)

    COVI - GUARD™ (STI - 1499)* 20 » A potent Anti - SARS - CoV - 2 antibody, COVI - GUARD demonstrated complete neutralization of infection in African green monkey kidney epithelial cells (VERO/E6 cells) in vitro at low concentrations. COVI - GUARD was similarly potent in preclinical studies for neutra

  21. Slide 21: COVI-AMG (STI-2020)

    COVI - AMG™ (STI - 2020)* 21 » COVI - AMG engineered for ultra - high potency, with an expected effective dose in humans suitable for IV push administration in an outpatient setting » COVI - AMG administered IV immediately following infection or 12 hours post - infection protects SARS - CoV - 2 - in

  22. Slide 22: COVI-DROPS (STI-2099)

    COVI - DROPS™ (STI - 2099)* 22 » COVI - DROPS is an intranasal formulation of the highly potent SARS - CoV - 2 neutralizing antibody STI - 2020 » A single intranasal administration of COVI - DROPS prevented disease - associated weight loss in treated hamsters. The impact of the treatment was observe

  23. Slide 23: Abivertinib (STI-5656): Severe COVID-19-Related Pulmonary Symptoms

    23 » STI - 5656 is in Phase 2 clinical studies as a treatment of severe COVID - 19 symptoms (ARDS). » STI - 5656 has been shown to be safe and well tolerated at doses up to 600 mg daily in the treatment of non - small cell lung cancer and B cell lymphomas. » STI - 5656 has shown potent (nanomolar) i

  24. Slide 24: COVI-MSC (STI-8282) for Patients with Acute Lung Damage

    24 » COVI - MSC (STI - 8282): Allogeneic culture - expanded adipose - derived Mesenchymal stem cells for the rescue of patients with lung damage and acute respiratory distress syndrome (ARDS) due to COVID - 19 » Preclinical studies have demonstrated that COVI - MSCs may produce a reduction in lung i

  25. Slide 25: Non-opioid Pain Programs

    Non - opioid Pain Programs 25 © 2021 Sorrento Therapeutics, Inc. All Rights Reserved

  26. Slide 26: Lead Marketed Product: ZTlido 1.8%

    Lead Marketed Product: ZTlido® 1.8% FDA approved for relief of pain associated with PHN Properties ZTlido® 1.8% Lidoderm® 5% Bioavailability ~45% ~3 + 2% Weight 2 g 14 g Thickness 0.8 mm 1.7 mm Lidocaine content 36 mg 700 mg Adhesive Non - aqueous Water - based ® • ZTlido sales exhibited continuous

  27. Slide 27: SP-102: Pivotal Phase 3 Trial

    SP - 102: Pivotal Phase 3 trial - Over 90% Enrolled If Approved Could be the First Steroid Formulation with an FDA - Approved Label to Treat Lumbar Radicular/Sciatica Pain Potent non - particulate steroid (injectable dexamethasone sodium phosphate gel) ᪵ Viscous g el formulation for extended local r

  28. Slide 28: Resiniferatoxin (RTX)

    Resiniferatoxin (RTX) 28 © 2021 Sorrento Therapeutics, Inc. All Rights Reserved Resiniferatoxin is a potent agonist of the transient receptor potential cation channel sub - family V member 1 (TRPV 1 ) predominantly found in a subpopulation of small C and A delta sensory neurons most often involved i

  29. Slide 29: Clinical Studies Status

    CLINICAL STUDIES STATUS (2020 COMPLETED ENROLLMENT) OA KNEE PAIN Phase 1b double - blinded, placebo - controlled study to assess the safety and preliminary efficacy of intra - articular administration of Resiniferatoxin or saline control (as placebo group) for the treatment of moderate to severe pai

  30. Slide 30: Study Results – Epidural Admin (Cancer Pain)

    Study Results – Epidural Admin (Cancer Pain) – Study Closed. INTRACTABLE CANCER PAIN A Multicenter, Open - Label, Phase 1b Study to Assess the Safety and Define the Maximally Tolerated Dose of Epidural Resiniferatoxin Injection for the Treatment of Intractable Pain Associated With Cancer www.clinica

  31. Slide 31: Study Results – Intra-articular Admin (OA Knee Pain)

    Study Results – Intra articular admin (OA Knee Pain). Study Closed. OA KNEE PAIN Phase 1b double - blinded, placebo - controlled study to assess the safety and preliminary efficacy of intra - articular administration of Resiniferatoxin or saline control (as placebo group) for the treatment of modera

  32. Slide 32: Persistence of Effect (OA Knee Pain)

    Persistence of Effect past Day 84 (OA Knee Pain) 32 © 2021 Sorrento Therapeutics, Inc. All Rights Reserved

  33. Slide 33: Immuno-Oncology Programs

    Immuno - Oncology Programs 33 © 2021 Sorrento Therapeutics, Inc. All Rights Reserved

  34. Slide 34: Core Oncology Pipeline Continues to Progress

    Core Oncology Pipeline Continues to Progress © 2021 Sorrento Therapeutics, Inc. All Rights Reserved 34

  35. Slide 35: Abivertinib (STI-5656): NSCLC and B Cell Lymphomas

    35 © 2021 Sorrento Therapeutics, Inc. All Rights Reserved ABIVERTINIB (STI - 5656): NSCLC and B Cell Lymphomas » Abivertinib maleate (STI - 5656) is a potent, small molecule third - generation tyrosine kinase inhibitor (TKI) of mutant epidermal growth factor receptor (EGFR) and Bruton tyrosine kinas

  36. Slide 36: 32 © 2021 Sorrento Therapeutics, Inc. All Rights Reserved

    32 © 2021 Sorrento Therapeutics, Inc. All Rights Reserved

Sorrento Therapeutics — Investor Presentation (January 2021) on 6ix